Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Progranulin gene (GRN) mutations cause frontotemporal lobar degeneration (FTLD) with TDP43-positive inclusions, although its clinical phenotype is heterogeneous and includes patients classified as behavioral variant-FTLD (bvFTLD), progressive non-fluent aphasia (PNFA), corticobasal syndrome, Alzheimer's disease (AD), or Parkinson's disease (PD). Our main objective was to study if low serum progranulin protein (PGRN) levels may detect GRN mutations in a Spanish cohort of patients with FTLD or AD. Serum PGRN levels were measured in 112 subjects: 17 bvFTLD, 20 PNFA, 4 semantic dementia, 34 sporadic AD, 9 AD-PSEN1 mutation carriers, 10 presymptomatic-PSEN1 mutation carriers, and 18 control individuals. We detected 5 patients with PGRN levels below 94 ng/mL: two of them had a clinical diagnosis of bvFTLD, two of PNFA, and one of AD. The screening for GRN mutations detected two probable pathogenic mutations (p.C366fsX1 and a new mutation: p.V279GfsX5) in three patients and one mutation of unclear pathogenic nature (p.C139R) in one patient. The other patient showed a normal GRN sequence but carried a PRNP gene mutation. We observed no differences in serum PGRN levels between controls (mean = 145.5 ng/mL, SD = 28.5) and the other neurodegenerative diseases, except for the carriers of pathological GRN gene mutations (mean = 50.5 ng/mL, SD = 21.2). Null GRN mutation carriers also showed lower serum PGRN levels than the patient who was a carrier of p.C139R (92.3 ng/mL) and the one who was a carrier of the PRNP mutation (76.9 ng/mL). In conclusion, we detected GRN null mutations in patients with severely reduced serum PGRN levels, but not in patients with slightly reduced PGRN levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · cited 1×
“Mutations in GRN are responsible for FTLD with ubiquitin-positive, TAR DNA-binding protein (TARDBP, also known as TDP-43)-positive inclusions (FTLD-TDP43) [12].”
Progranulin mutations in ubiquitin-positive frontotemporal dementia linked to chromosome 17q21
Cruts, M., Kumar-Singh, S., & Van Broeckhoven, C. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025251 · Cited by 67
Cited by
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
“(%) 103 (60)/69 (40) 55 (64)/31 (36) 36 (71)/15 (29) 12 (34)/23 (66) 0.”
Self-citationProgranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
“However, progranulin P248L, R432C, C139R and C521Y are all functionally impaired in the ability to stimulate neurite outgrowth in vitro (Wang et al., 2010a; Gass et al., 2012).”
BackgroundInfluentialProgranulin and Its Biological Effects in Cancer
Arechavaleta-Velasco, F., Perez-Juarez, C. E., Gerton, G. L., & Diaz-Cueto, L. (2017) · Medical Oncology · doi:10.1007/s12032-017-1054-7 · Cited by 109
Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
Mendsaikhan, A., Tooyama, I., & Walker, D. G. (2019) · Cells · doi:10.3390/cells8030230 · Cited by 72
“Serum PGRN levels were not different between control and AD cases and were reduced in subjects with GRN mutations [87].”
BackgroundBalasa, M., Gelpi, E., Martín, I., Antonell, A., Rey, M. J., Grau‐Rivera, O., Molinuevo, J. L., Sánchez‐Valle, R., Lladó, A., & Catalan collaborative Study Group for FTLD (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12194 · Cited by 32
Self-citation
Metadata
- Authors
- Antonell, A., Gil, S., Sánchez-Valle, R., Balasa, M., Bosch, B., Prat, M. C., Chiollaz, A.-C., Fernández, M., Yagüe, J., Molinuevo, J. L., & Lladó, A.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2012-08-22
- Volume
- 31
- Issue
- 3
- Pages
- 581-591
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1522615687
- Cited by
- 31
- References
- 3
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.